<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7464065\results\search\testTrace\results.xml">
  <result pre="been conducted to understand the molecular basis of the SARS-CoV-2" exact="infection" post="and evolution, develop effective therapeutics, antiviral drugs, and vaccines,"/>
  <result pre="of the coronaviruses, including the SARS-CoV-2, and recent advances in" exact="diagnosis" post="and vaccine development in brief and focusing mainly on"/>
  <result pre="1), the transmission rate of COVID-19 is much higher, alarming" exact="infection" post="to an average of two to three individuals getting"/>
  <result pre="and then documented to affect humans leading to mainly respiratory" exact="infection" post="and also to cause multiple system infection, the virus"/>
  <result pre="infection and also to cause multiple system infection, the virus" exact="infection" post="has also been reported from few animals such as"/>
  <result pre="and host proteins, have been explored along with the experimental" exact="testing" post="of anti-viral properties of small compounds [31â€&quot;33]. To date,"/>
  <result pre="of the coronaviruses, including the SARS-CoV-2 highlights few advances in" exact="diagnosis" post="and vaccine development [34]. It elaborately emphasizes on the"/>
  <result pre="markets of China. The employment of control measures inclusive of" exact="quarantine" post="and air travel blockade[62], ultimately resulted in the disappearance"/>
  <result pre="of the general public, along with nurses involved in the" exact="treatment" post="of COVID-19 patients was evaluated based on vicarious traumatization"/>
  <result pre="SARS-CoV, MERS-CoV, and now SARS-CoV-2. Seldom coronaviruses cause lower respiratory" exact="infection" post="or pneumonia but SARS-CoV-2 causes. Coronaviruses have seasonal pattern"/>
  <result pre="patient in Wuhan, China suggesting the need for rapid clinical" exact="diagnosis" post="followed by favourable hydration treatment to reduce the risk"/>
  <result pre="the need for rapid clinical diagnosis followed by favourable hydration" exact="treatment" post="to reduce the risk of severe outcomes as a"/>
  <result pre="[30], but even dysgeusia and anosmia [27, 78]. Moreover, SARS-CoV" exact="infection" post="has been reported in the nervous tissue of experimental"/>
  <result pre="are in use currently for the laboratory confirmation of coronavirus" exact="infection" post="[87â€&quot;89]. Full genome sequencing is the ultimate tool to"/>
  <result pre="real-time PCR assay (rRT-PCR) is required for useful and timely" exact="screening" post="of COVID-19 patients, which can be carried out in"/>
  <result pre="SARS-CoV-2 N and ORF1ab regions has been developed [41]. Moreover," exact="testing" post="for COVID-19 requires travelling to a clinical setting that"/>
  <result pre="kit was approved (RocheÂ®). There are several quick tests for" exact="detection" post="of IgM and IgG, but they were not extensively"/>
  <result pre="the Ebola outbreak in 2014â€&quot;2015 [107]. During this outbreak, special" exact="quarantine" post="rules and protocols were set up to limit and"/>
  <result pre="immediate treatment. The below sections will emphasize on different potential" exact="treatment" post="options that could be pursued for therapy despite limited"/>
  <result pre="reviewed, two treatments currently authorized for emergency use however no" exact="treatment" post="is yet approved by FDA [113]. Of these treatments"/>
  <result pre="treating COVID-19 patients [115]. Developing neutralizing antibodies In general, the" exact="infection" post="of coronavirus starts with the entry of S protein,"/>
  <result pre="models to confirm that they can neutralize the SARS-CoV-2 disease" exact="infection" post="[47, 125, 126]. The alternate strategy of generating the"/>
  <result pre="advantages, such as simplifying production and manufacturing. For a shorter" exact="treatment" post="strategy, this could quickly help in the SARS-CoV-2 outbreak."/>
  <result pre="immediate in use, it is short-lived. It has limitations of" exact="infection" post="transmission, abnormal reactions, and the possibility of other severe"/>
  <result pre="in vitro [35] effectively. They were able to block virus" exact="infection" post="at low concentrations (micromolar) and showed a high selectivity"/>
  <result pre="the effectiveness or safety of hydroxychloroquine or chloroquine for the" exact="treatment" post="of COVID-19 in hospitalized patients as a systematic living"/>
  <result pre="is required to improve their safety and effectiveness for the" exact="treatment" post="of COVID-19 [154]. Alpha-lipoic acid, baloxavir, colchicine, interferon, lopinavir/ritonavir,"/>
  <result pre="serum of patients who just recovered from the active viral" exact="infection" post="to treat patients who contract in the future [160]."/>
  <result pre="supported the use of dromedary immune serum in preventing MERS-CoV" exact="infection" post="[162]. Patients who have 100% recovery from the novel"/>
  <result pre="therapy [165]. It is the earliest and available means of" exact="treatment" post="and provides antibodies that help in neutralizing SARS-CoV-2 however"/>
  <result pre="recombinant interferon-Î²1b (IFN-Î²1b) have been found useful in treating MERS-CoV" exact="infection" post="[110, 170, 171]. Hence, these are being explored as"/>
  <result pre="is required [174]. Efficacy of remdesivir against SARS-CoV-2 is under" exact="testing" post="by Gilead Sciences (NASDAQ-GILD) pharmaceutical company (https://www.fool.com/investing/2020/03/04/is-gilead-sciences-the-best-buy-in-the-coronavirus.aspx). National Health"/>
  <result pre="patients, in its revised guidelines for the prevention, diagnosis, and" exact="treatment" post="of pneumonia developed due to COVID-19 infection in the"/>
  <result pre="prevention, diagnosis, and treatment of pneumonia developed due to COVID-19" exact="infection" post="in the vast populous country [175, 176]. Future research"/>
  <result pre="and they have shown safety hence can be considered as" exact="treatment" post="options [18]. EIDD-2801 compound has proven effective against influenza"/>
  <result pre="by the lopinavir (LPV), and it is proposed as a" exact="treatment" post="option for ongoing COVID-19 infection [174]. Further, a novel"/>
  <result pre="it is proposed as a treatment option for ongoing COVID-19" exact="infection" post="[174]. Further, a novel vinylsulfone protease inhibitor suggested treating"/>
  <result pre="a Deep Docking (DD) platform was used for structure-based virtual" exact="screening" post="of nearly 1.3 billion molecules with the potential of"/>
  <result pre="known that ACE2 is a crucial player in the coronavirus" exact="infection" post="by promoting cell entry [181]. The metallopeptidase, ACE2, has"/>
  <result pre="SARS-CoV [183]. ACE2 is an important drug target for the" exact="treatment" post="of cardiovascular and kidney diseases [85, 184]. Recently, Lei"/>
  <result pre="neutralizing activity. These ACE2 fusion proteins could be used for" exact="diagnosis" post="and as research reagents in the development of vaccines"/>
  <result pre="China recommended a combination of ribavirin and interferon-Î± as a" exact="treatment" post="regimen for COVID-19 in its fifth edition; however, the"/>
  <result pre="amoxicillin), corticosteroids and oxygen therapy has been used in COVID-19" exact="treatment" post="[189]. Corticosteroids have been routinely used for the treatment"/>
  <result pre="COVID-19 treatment [189]. Corticosteroids have been routinely used for the" exact="treatment" post="of Th1 and Th2 induced lung injury reported in"/>
  <result pre="drugs like ShuFengJieDu and Lianhuaqingwen were also used in the" exact="treatment" post="of COVID-19, but their efficacy needs to be determined"/>
  <result pre="contrast to this, WHO has indicated that currently no effective" exact="treatment" post="for SARS-CoV-2 is known and use of different antibiotics,"/>
  <result pre="of its efficacy against SARS-CoV-2 [49]. For safe and successful" exact="treatment" post="of severe respiratory illness in infants and children, the"/>
  <result pre="prevent virus entry and hence a strategy for controlling viral" exact="infection" post="[201]. Targeting S protein can both develop both cellular"/>
  <result pre="technology. Further, identifying diagnostic markers are vital. Similarly, for the" exact="treatment" post="purpose, novel drugs or therapeutic agents are being explored"/>
  <result pre="[231], enzyme inhibitors [232], antivirals [228, 233], immunomodulatory [234], and" exact="treatment" post="adjuvants [235]. That is the primary class that has"/>
  <result pre="coronavirus, and which can be used therapeutically for an existing" exact="infection" post="with the rabies virus and a coronavirus to treat"/>
  <result pre="methods of using the same to treat or prevent viral" exact="infection" post="and disease from coronaviruses, caliciviruses, and picornaviruses Chang et"/>
  <result pre="inhibitors This invention pertains to materials and methods for the" exact="treatment" post="of patients with coronavirus infection and the control of"/>
  <result pre="materials and methods for the treatment of patients with coronavirus" exact="infection" post="and the control of zoonotic disease outbreaks using broad-spectrum"/>
  <result pre="use of said compounds, combinations, compositions and medicaments, in the" exact="treatment" post="of diseases in which modulation of STING (Stimulator of"/>
  <result pre="[265] 2017-01-19 WO2017010835A1 Drug/treatment Use of radotinib for prevention or" exact="treatment" post="of viral respiratory disease The present invention relates to"/>
  <result pre="compound of Chemical FormulaÂ 1 (radotinib) in the prevention or" exact="treatment" post="of viral respiratory disease. According to the present invention,"/>
  <result pre="salt thereof can be used for the prevention, alleviation, or" exact="treatment" post="of coronavirus infection. Specifically, the present invention can be"/>
  <result pre="used as a useful antiviral agent for the prevention or" exact="treatment" post="of disease caused by infection of the Middle East"/>
  <result pre="agent for the prevention or treatment of disease caused by" exact="infection" post="of the Middle East respiratory syndrome-coronavirus (MERS-CoV). Kim et"/>
  <result pre="and are suitable for the demands for quick and accurate" exact="detection" post="of modernized cultivation farms Wei et al. [229] 2016-06-1"/>
  <result pre="cultivation farms Wei et al. [229] 2016-06-1 CN105671006A Diagnosis and" exact="treatment" post="High-efficiency ranilla luciferase gene expression recombinant HCoV-OC43 (human coronavirus"/>
  <result pre="recombinant human coronavirus OC43 virus and application thereof to a" exact="screening" post="of antiviral medicines. By an overlap PCR (polymerase chain"/>
  <result pre="the virus rOC43-ns2DelRluc can be successfully applied to antiviral medicine" exact="screening" post="experiments and has an extensive application prospect in high-throughput"/>
  <result pre="screening experiments and has an extensive application prospect in high-throughput" exact="screening" post="of anti-coronavirus medicines and host antiviral genes Shenliang, [228]"/>
  <result pre="in preparation of drugs used for preventing or treating coronavirus" exact="infection" post="Rao et al. [266] 2016-09-01 WO2016138160A1 Recombinant peptides/antibodies treatment"/>
  <result pre="coronavirus infection Rao et al. [266] 2016-09-01 WO2016138160A1 Recombinant peptides/antibodies" exact="treatment" post="Middle east respiratory syndrome coronavirus immunogens, antibodies, and their"/>
  <result pre="is a protective immune response that inhibits or prevents MERS-CoV" exact="infection" post="in the subject. Recombinant MERS-CoV polypeptides and nucleic acid"/>
  <result pre="as well as methods of preventing and treating a MERS-CoV" exact="infection" post="in a subject Graham et al. [267] 2016-06-01 CN105624122A"/>
  <result pre="virus strain Liao et al. 2016[268] 2017-08-08 CN107022008A Prevention and" exact="treatment" post="Suppress polypeptide and its application of human coronavirusâ€™s infection"/>
  <result pre="and treatment Suppress polypeptide and its application of human coronavirusâ€™s" exact="infection" post="broad spectrum The invention belongs to the biomedicine field."/>
  <result pre="syncretizing mechanisms provide can be to the polypeptide of the" exact="infection" post="with broad-spectrum inhibitory action of two or more human"/>
  <result pre="present invention can provide the drug candidate for prevention and" exact="treatment" post="for the novel human coronavirus for being still possible"/>
  <result pre="[269] 2018-02-13 US9889194B Immunogenic proteins Immunogenic composition for MERS coronavirus" exact="infection" post="Described herein are immunogenic compositions for preventing infection with"/>
  <result pre="MERS coronavirus infection Described herein are immunogenic compositions for preventing" exact="infection" post="with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the"/>
  <result pre="activity, thus providing a means of treating or preventingÂ MERSÂ" exact="infection" post="in humans. In some embodiments, the invention provides for"/>
  <result pre="specifically, a microfluidic device for detecting pathogen genes, and a" exact="detection" post="method using the same. Therefore, the present invention can"/>
  <result pre="disease, or disorder Brennan et al. [281] 2019-06-04 US10307439B2 Drug" exact="treatment" post="Substituted nucleosides, nucleotides and analogues thereof Disclosed herein are"/>
  <result pre="a Togaviridae virus, a Hepeviridae virus and a Bunyaviridae virus" exact="infection" post="with one or more nucleosides, nucleotides and nucleotide analogue"/>
  <result pre="high toll rates alone in China itself, most likely. The" exact="infection" post="is spreading across the globe. There are no licensed"/>
  <result pre="adding broad-spectrum antivirals such as remdesivir, chloroquine, or lopinavir/ritonavir. Passive" exact="treatment" post="by Î±-interferon atomization inhalation, immunoglobulin G therapy, or plasma"/>
  <result pre="East Respiratory Syndrome Coronavirus (MERS-CoV) infection: extent and implications for" exact="infection" post="control: A systematic reviewTravel Med Infect Dis201927273230550839 13.BaharoonSMemishZAMERS-CoV as"/>
  <result pre="potential relationship with the SARS-CoV-2 divergenceCurr Trop Med Rep.2020737578 30.Villamizar-PenaRGutierrez-OcampoERodriguez-MoralesAJPooled" exact="prevalence" post="of diarrhea among COVID-19 PatientsClin Gastroenterol Hepatol.202018102385238732425705 31.GuiMSongWZhouHXuJChenSXiangYWangXCryo-electron microscopy"/>
  <result pre="S, Mei J, Wu Z, Deng Y, et al. Clinical" exact="diagnosis" post="of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv."/>
  <result pre="et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statement. World J Pediatr. 2020."/>
  <result pre="Organization 65.World Health O: Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus; infection is suspected: interim guidance, 28"/>
  <result pre="Clinical management of severe acute respiratory infection when novel coronavirus;" exact="infection" post="is suspected: interim guidance, 28 January 2020. Geneva: World"/>
  <result pre="MuÃ±ozAJGarcÃ­aALOspina SerranoAVEscobarBPAcevedo MedinaCAet al.Colombian consensus recommendations for diagnosis, management and" exact="treatment" post="of the infection by SARS-COV-2/ COVID-19 in health care"/>
  <result pre="al.Colombian consensus recommendations for diagnosis, management and treatment of the" exact="infection" post="by SARS-COV-2/ COVID-19 in health care facilities - Recommendations"/>
  <result pre="Dong X, Li X, Li J et al. Rapid colorimetric" exact="detection" post="of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal"/>
  <result pre="diagnostic plat-form: iLACO. medRxiv 2020:2020.2002.2020.20025874. 89.ZhangNWangLDengXLiangRSuMHeCHuLSuYRenJYuFet al.Recent advances in the" exact="detection" post="of respiratory virus infection in humansJ Med Virol202092440841731944312 90.CormanVEckerleIBleickerTZakiALandtOEschbach-BludauMvan"/>
  <result pre="2020:2020.2002.2020.20025874. 89.ZhangNWangLDengXLiangRSuMHeCHuLSuYRenJYuFet al.Recent advances in the detection of respiratory virus" exact="infection" post="in humansJ Med Virol202092440841731944312 90.CormanVEckerleIBleickerTZakiALandtOEschbach-BludauMvan BoheemenSGopalRBallhauseMBestebroerTDetection of a novel"/>
  <result pre="101.collab: Health Commission ChinaExpert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumoniaChin J Tuberculosis Respir Dis2020433185188 102.LiHWangYMXuJYCaoBPotential"/>
  <result pre="104.NishiuraHMizumotoKVillamil-GomezWERodriguez-MoralesAJPreliminary estimation of the basic reproduction number of Zika virus" exact="infection" post="during Colombia epidemic, 2015-2016Travel Med Infect Dis201614327427627060613 105.Rodriguez-MoralesAJZika and"/>
  <result pre="threat for pregnant travelers?Travel Med Infect Dis20161415626879565 106.QiuHBLiXYDuBKangHYJWangYSWangFSunBTongZHThe keypoints in" exact="treatment" post="of the critical coronavirus disease 2019 patient(1)Zhonghua Jie He"/>
  <result pre="an update on its 40 yearâ€™s journeyVet Quart201737198135 108.KilianskiABakerSCCell-based antiviral" exact="screening" post="against coronaviruses: developing virus-specific and broad-spectrum inhibitorsAntiviral Res201410110511224269477 109.PillaiyarTMeenakshisundaramSManickamMRecent"/>
  <result pre="a Nonhuman Primate Model of Common MarmosetJ Infect Dis2015212121904191326198719 111.LuHDrug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)BioScience Trends2020141697131996494 112.ZumlaAChanJFWAzharEIHuiDSCYuenK-YCoronaviruses -"/>
  <result pre="SystemsKona201633638527081214 131.ThiEPLeeACHGeisbertJBUrsic-BedoyaRAgansKNRobbinsMDeerDJFentonKAKondratowiczASMacLachlanIet al.Rescue of non-human primates from advanced Sudan ebolavirus" exact="infection" post="with lipid encapsulated siRNANat Microbiol2016110161421614227670117 132.ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAet al.Lipid nanoparticle siRNA"/>
  <result pre="infection with lipid encapsulated siRNANat Microbiol2016110161421614227670117 132.ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAet al.Lipid nanoparticle siRNA" exact="treatment" post="of Ebola-virus-Makona-infected nonhuman primatesNature2015521755236236525901685 133.DunningJSahrFRojekAGannonFCarsonGIdrissBMassaquoiTGandiRJosephSOsmanHKet al.Experimental treatment of ebola"/>
  <result pre="al.Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesNature2015521755236236525901685 133.DunningJSahrFRojekAGannonFCarsonGIdrissBMassaquoiTGandiRJosephSOsmanHKet al.Experimental" exact="treatment" post="of ebola virus disease with TKM-130803: A Single-Arm Phase"/>
  <result pre="2020. 146.GeversSKwaMSGWijnansEvan NieuwkoopCSafety considerations for chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19Clin Microbiol Infect20202691276127732422406 147.LiLWangXWangRHuYJiangSLuXAntiviral Agent Therapy Optimization in"/>
  <result pre="condition. Int J Infect Dis. 2020. 156.PanXDongLYangLChenDPengCPotential drugs for the" exact="treatment" post="of the novel coronavirus pneumonia (COVID-19) in ChinaVirus Res202028619805732531236"/>
  <result pre="160.MireCEGeisbertJBAgansKNThiEPLeeACHFentonKAGeisbertTWPassive immunotherapy: assessment of convalescent serum against ebola virus makona" exact="infection" post="in nonhuman primatesJ Infect Dis2016214suppl 3S367S37427571900 161.FocosiDAndersonAOTangJWTuccoriMConvalescent plasma therapy"/>
  <result pre="StatesClin Infect Dis201561449650225904375 165.JinY-HCaiLChengZ-SChengHDengTFanY-PFangCHuangDHuangL-QHuangQet al.A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="Dis201561449650225904375 165.JinY-HCaiLChengZ-SChengHDengTFanY-PFangCHuangDHuangL-QHuangQet al.A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil"/>
  <result pre="viral polymeraseCurr Pharm Des200612111339135516611119 169.ChuCMChengVCCHungIFNWongMMLChanKHChanKSKaoRYTPoonLLMWongCLPGuanYet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax200459325225614985565 170.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSKojanSAl"/>
  <result pre="SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19" exact="treatment" post="optionJ Med Virol202010.1002/jmv.2572932648948 175.GaoJTianZYangXBreakthrough: Chloroquine phosphate has shown apparent"/>
  <result pre="Med Virol202010.1002/jmv.2572932648948 175.GaoJTianZYangXBreakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBioScience Trends2020141727332074550 176.LinLLiTSInterpretation"/>
  <result pre="yi xue za zhi20201001180580732234150 177.FanH-HWangL-QLiuW-LAnX-PLiuZ-DHeX-QSongL-HTongY-GRepurposing of clinically approved drugs for" exact="treatment" post="of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus"/>
  <result pre="Transl Med201911515eaax586631645453 179.MorseJSLalondeTXuSLiuWRLearning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChemBioChem202021573073832022370"/>
  <result pre="pneumoniaZhonghua Jie He He Hu Xi Za Zhi202043E01432061198 188.MatsuyamaSNaoNShiratoKKawaseMSaitoSTakayamaINagataNSekizukaTKatohHKatoFet al.Enhanced" exact="isolation" post="of SARS-CoV-2 by TMPRSS2-expressing cellsProc Natl Acad Sci202011713700132165541 189.ZhangJZhouLYangYPengWWangWChenXTherapeutic"/>
  <result pre="Med202083e11e1232061335 190.Macauley P, Martin A, Epelbaum O: CORTICOSTEROIDS in the" exact="treatment" post="of severe covid-19 lung disease: the pulmonology perspective from"/>
  <result pre="support strategy of severe acute respiratory failure caused by SARS-CoV-2" exact="infection" post="in childrenZhongguo Dang Dai Er Ke Za Zhi202022318319432204751 196.BaronSADevauxCColsonPRaoultDRolainJ-MTeicoplanin:"/>
  <result pre="Er Ke Za Zhi202022318319432204751 196.BaronSADevauxCColsonPRaoultDRolainJ-MTeicoplanin: an alternative drug for the" exact="treatment" post="of coronavirus COVID-19Int J Antimicrob Agents2020105944 197.CeccarelliGAlessandriFdâ€™EttorreGBorrazzoCSpagnolelloOOlivaARubertoFMastroianniCMPuglieseFVendittiMet al.Is teicoplanin"/>
  <result pre="coronavirus COVID-19Int J Antimicrob Agents2020105944 197.CeccarelliGAlessandriFdâ€™EttorreGBorrazzoCSpagnolelloOOlivaARubertoFMastroianniCMPuglieseFVendittiMet al.Is teicoplanin a complementary" exact="treatment" post="option for COVID-19? The question remainsInt J Antimicrob Agents202056210602910602932454071"/>
  <result pre="Song SE, Park JS. Use of radotinib for prevention or" exact="treatment" post="of viral respiratory disease. 2017. 233.Radtke KL PH, Neyts"/>
  <result pre="Wang W, Li B, Li J, Yuan Y. First successful" exact="treatment" post="of a COVID-19 pregnant woman with severe ARDS by"/>
  <result pre="have we learned? J Infect Public Health. 2020. 252.PrajapatMShekharNSarmaPAvtiPSinghSKaurHBhattacharyyaAKumarSSharmaSPrakashAet al.Virtual" exact="screening" post="and molecular dynamics study of approved drugs as inhibitors"/>
  <result pre="Y: Suppress polypeptide and its application of human coronary virusâ€™s" exact="infection" post="wide spectrum. 2017. 270.Jiang S DL, Zhou Y, Zhao"/>
 </snippets>
</snippetsTree>
